美国的 Amneal 将收购 Kashiv BioSciences, 以创造全球生物类似药品领导者. Amneal to acquire Kashiv BioSciences to create global biosimilar leader.

美国药业公司将收购Kashiv BioSciences, 以创造一个全球生物类似制剂领导者. Amneal Pharmaceuticals will acquire Kashiv BioSciences to create a global biosimilar leader. 这笔交易预计将于2026年底完成, 结合了Kashiv的制造专业知识和Amneal的商业实力. The deal, expected to close in late 2026, combines Kashiv's manufacturing expertise with Amneal's commercial strength. 合并的目的是扩大对负担得起的生物疗法的获取, 并加强两家公司在不断增长的仿生药市场上的地位. The merger aims to expand access to affordable biologic therapies and strengthen both companies' positions in the growing biosimilars market.